Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Epidemiología Y Salud Pública (16)

2023

  1. Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia

    International Journal of Molecular Sciences, Vol. 24, Núm. 12

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

2021

  1. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 45-58

  2. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  3. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 59-70

2020

  1. A compendium answering 150 questions on COVID-19 and SARS-CoV-2

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2503-2541

  2. Allergic rhinitis

    Nature Reviews Disease Primers, Vol. 6, Núm. 1

  3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  5. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

2018

  1. Translational science in albuminuria: A new view of de novo albuminuria under chronic RAS suppression

    Clinical Science, Vol. 132, Núm. 7, pp. 739-758

2016

  1. High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study

    Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307

2014

  1. Predictive factors of severe multilobar pneumonia and shock in patients with influenza

    Emergency Medicine Journal, Vol. 31, Núm. 4, pp. 301-307

2013

  1. Benefit of conjugate pneumococcal vaccination in preventing influenza hospitalization in children: A case-control study

    Pediatric Infectious Disease Journal, Vol. 32, Núm. 4, pp. 330-334

  2. Risk factors and effectiveness of preventive measures against influenza in the community

    Influenza and other Respiratory Viruses, Vol. 7, Núm. 2, pp. 177-183

2012

  1. Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization

    Preventive Medicine, Vol. 54, Núm. 6, pp. 434-439